Data on 1,479 patients with type 2 diabetes and stable coronary disease revealed 24.1% of those who received insulin-providing medications to regulate blood glucose levels developed peripheral arterial disease at 4.6 years, compared with 16.9% in those who took insulin-sensitizing drugs. Researchers also found patients on insulin sensitizers showed reduced rates of amputation, lower-extremity revascularization and low ankle-brachial index than those who received insulin-providing drugs. The results appear in Diabetes Care.
Diabetes patients on insulin sensitizers have lower PAD risk
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||